Abstract: Tetrahydroazeto[2,1-a]isoquinoline of the formula (I): ##STR1## wherein R, R.sup.1, R.sup.2 and R.sup.3 are substituents and x and y are 0-2. Also pharmaceutical compositions for relieving depression in mammals, e.g. in humans, and methods for synthesis and use of formula (I) compounds as well as novel intermediates in the synthesis.

Abstract: Dialkanolamines and nontoxic pharmaceutically-acceptable acid-addition salts of the compounds of the following formula ##STR1## wherein R.sub.1 is hydrogen lower alkyl, or fluoro; R.sub.2 is hydrogen or lower alkyl; R.sub.3 and R.sub.4 are the same or different and selected from the group consisting of hydrogen or lower alkyl or R.sub.3 and R.sub.4 together define a chemical bond directly linking the two alkanol chains so as to form a pyrrolidine ring; Ar, is phenyl or thienyl or phenyl substituted with one to three substituents selected from the group consisting of lower alkyl and halo; and Ar.sub.2 is phenyl and phenyl substituted with one to three substituents selected from the group consisting of lower alkyl and halo which have antidepressant activity.

Abstract: Novel compounds are disclosed, which are derivatives of 1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]-isoquinolines, represented by general formula (I): ##STR1## as well as pharmaceutical compositions and methods for the treatment of depression in warm-blooded animals, e.g., man. Novel intermediates are also part of the invention.

Abstract: Sulfamates of the following formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are as herein defined have been found to exhibit anticonvulsant activity and are thus useful in the treatment of conditions such as epilepsy. Further, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and intermediates form part of the present invention.

Abstract: Sulfamates of the following formula (I): ##STR1## wherein X is O or CH.sub.2 and R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as herein defined have been found to exhibit anticonvulsant activity and are thus useful in the treatment of conditions such as epilepsy. Further, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and intermediates form part of the present invention.

Abstract: Hexahydroindolizines of the following formulae (I) and (II): ##STR1## are novel and have been found to possess antisecretory and antidepressant properties. Methods of preparation, intermediates thereto and use are also disclosed.

Abstract: Sulfamates of the following formula (I): ##STR1## wherein X is O or CH.sub.2 and R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as herein defined have been found to exhibit anticonvulsant activity and are thus useful in the treatment of conditions such as epilepsy. Further, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and intermediates form part of the present invention.

Abstract: Pyrimido[6,1-a]isoquinoline-4-one derivatives of the formula: ##STR1## wherein R is C.sub.1 -C.sub.6 lower alkyl or 2-haloethyl (halo=Cl, Br or I) having antihypertensive activity.

Abstract: 2-Ureido-7-phenylhexahydrobenzo[a]quinolizines of the structural formula, ##STR1## wherein R.sub.1 =H or lower alkyl (one to three carbons) and R.sub.2 =H, lower alkyl (one to six carbons), or phenyl, and which exhibit antihypertensive activity.

Abstract: A method for reducing indole compounds to the corresponding indoline compounds substantially free of undesirable side reactions is described. The method involves contacting an indole compound with a borane complex reagent in the presence of trifluoroacetic acid. The method is rapidly and readily carried out and provides an excellent method for preparing certain indoline compounds from the corresponding indole compounds. A novel dioxyborane useful as a borane reagent is also disclosed.

Abstract: A process for the preparation of loweralkyl 2-(N-R'-pyrryl)-.alpha.- loweralkanoic acid esters in increased yield and/or isomeric purity, and copper (II) 1,3-diketonate, copper (II) salicylaldehyde, copper (II) monoamino-1,3-diketonate, and copper (II) salicylaldimine complexes useful as promoting agents for said process.